News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
585,768 Results
Type
Article (40088)
Company Profile (96)
Press Release (545574)
Multimedia
Podcasts (119)
Webinars (21)
Section
Business (170697)
Career Advice (2042)
Deals (25463)
Drug Delivery (108)
Drug Development (71366)
Employer Resources (125)
FDA (14549)
Job Trends (12265)
News (287154)
Policy (26677)
Tag
Academia (2523)
Academic (2)
Accelerated approval (11)
Adcomms (21)
Allergies (94)
Alliances (44905)
ALS (118)
Alzheimer's disease (1403)
Antibody-drug conjugate (ADC) (168)
Approvals (14605)
Artificial intelligence (359)
Autoimmune disease (41)
Automation (20)
Bankruptcy (214)
Best Places to Work (9922)
BIOSECURE Act (21)
Biosimilars (106)
Biotechnology (66)
Bladder cancer (105)
Brain cancer (38)
Breast cancer (398)
Cancer (3128)
Cardiovascular disease (257)
Career advice (1719)
Career pathing (31)
CAR-T (195)
CDC (39)
Cell therapy (537)
Cervical cancer (25)
Clinical research (59397)
Collaboration (1166)
Company closure (2)
Compensation (499)
Complete response letters (32)
COVID-19 (2348)
CRISPR (63)
C-suite (417)
Cystic fibrosis (107)
Data (3478)
Decentralized trials (2)
Denatured (33)
Depression (64)
Diabetes (377)
Diagnostics (5404)
Digital health (26)
Diversity (7)
Diversity, equity & inclusion (40)
Drug discovery (166)
Drug pricing (135)
Drug shortages (32)
Duchenne muscular dystrophy (150)
Earnings (69612)
Editorial (49)
Employer branding (16)
Employer resources (112)
Events (90248)
Executive appointments (841)
FDA (16527)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (2)
Frontotemporal dementia (9)
Funding (957)
Gene editing (130)
Generative AI (34)
Gene therapy (406)
GLP-1 (891)
Government (3871)
Grass and pollen (5)
Guidances (314)
Healthcare (16551)
HIV (38)
Huntington's disease (25)
IgA nephropathy (42)
Immunology and inflammation (157)
Immuno-oncology (14)
Indications (44)
Infectious disease (2527)
Inflammatory bowel disease (153)
Inflation Reduction Act (11)
Influenza (71)
Intellectual property (139)
Interviews (371)
IPO (11619)
IRA (51)
Job creations (2724)
Job search strategy (1451)
Kidney cancer (7)
Labor market (46)
Layoffs (414)
Leadership (24)
Legal (6129)
Liver cancer (77)
Longevity (10)
Lung cancer (457)
Lymphoma (231)
Machine learning (15)
Management (41)
Manufacturing (466)
MASH (109)
Medical device (10977)
Medtech (10991)
Mergers & acquisitions (14591)
Metabolic disorders (960)
Multiple sclerosis (108)
NASH (17)
Neurodegenerative disease (133)
Neuropsychiatric disorders (29)
Neuroscience (2132)
NextGen: Class of 2025 (5608)
Non-profit (4201)
Now hiring (40)
Obesity (483)
Opinion (242)
Ovarian cancer (101)
Pain (122)
Pancreatic cancer (127)
Parkinson's disease (185)
Partnered (19)
Patents (319)
Patient recruitment (243)
Peanut (43)
People (49958)
Pharmaceutical (30)
Pharmacy benefit managers (16)
Phase I (18304)
Phase II (25910)
Phase III (19896)
Pipeline (2237)
Policy (237)
Postmarket research (2459)
Preclinical (7783)
Press Release (69)
Prostate cancer (157)
Psychedelics (33)
Radiopharmaceuticals (223)
Rare diseases (473)
Real estate (5121)
Recruiting (47)
Regulatory (19367)
Reports (37)
Research institute (2257)
Resumes & cover letters (312)
Rett syndrome (12)
RNA editing (9)
RSV (55)
Schizophrenia (97)
Series A (165)
Series B (114)
Service/supplier (7)
Sickle cell disease (65)
Special edition (17)
Spinal muscular atrophy (126)
Sponsored (31)
Startups (2848)
State (1)
Stomach cancer (12)
Supply chain (82)
Tariffs (66)
The Weekly (84)
Vaccines (822)
Venture capital (48)
Weight loss (337)
Women's health (41)
Worklife (17)
Date
Today (38)
Last 7 days (338)
Last 30 days (1851)
Last 365 days (28402)
2025 (19689)
2024 (30526)
2023 (33780)
2022 (44102)
2021 (46931)
2020 (45346)
2019 (39807)
2018 (29973)
2017 (27392)
2016 (26658)
2015 (30687)
2014 (24820)
2013 (21375)
2012 (22114)
2011 (22680)
2010 (21045)
Location
Africa (732)
Alabama (72)
Alaska (6)
Arizona (177)
Arkansas (11)
Asia (39044)
Australia (5327)
California (7474)
Canada (2184)
China (823)
Colorado (317)
Connecticut (352)
Delaware (220)
Europe (77843)
Florida (1075)
Georgia (257)
Hawaii (2)
Idaho (41)
Illinois (619)
India (39)
Indiana (342)
Iowa (17)
Japan (249)
Kansas (92)
Kentucky (28)
Louisiana (16)
Maine (35)
Maryland (1007)
Massachusetts (5610)
Michigan (237)
Minnesota (393)
Mississippi (3)
Missouri (77)
Montana (27)
Nebraska (20)
Nevada (84)
New Hampshire (51)
New Jersey (2159)
New Mexico (25)
New York (2086)
North Carolina (1052)
North Dakota (10)
Northern California (3354)
Ohio (223)
Oklahoma (18)
Oregon (30)
Pennsylvania (1508)
Puerto Rico (11)
Rhode Island (41)
South America (1020)
South Carolina (38)
South Dakota (1)
Southern California (2913)
Tennessee (128)
Texas (1138)
United States (27369)
Utah (218)
Virginia (185)
Washington D.C. (73)
Washington State (612)
West Virginia (4)
Wisconsin (76)
585,768 Results for "novo nordisk china r and d center".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
GLP-1
A Compounding Problem: How GLP-1s Drove Novo Nordisk’s Rapid Rise and Fall
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma recover?
August 13, 2025
·
5 min read
·
Nick Paul Taylor
Layoffs
Novo’s Headcount Rose 81% in Five Years as Revenue Climbed
As Novo Nordisk cuts 9,000 people from its organization in a restructuring effort,
BioSpace
looks back on the Danish pharma company’s rise.
September 10, 2025
·
1 min read
·
Annalee Armstrong
Obesity
Novo Seeks RNA Approach to Obesity, Diabetes With $550M Replicate Deal
Novo Nordisk has brought on other cardiometabolic collaborators this year, including United Laboratories International and Deep Apple Therapeutics.
August 28, 2025
·
1 min read
·
Tristan Manalac
Cardiovascular disease
Novo’s Wegovy Cuts Cardio Risk by 57% Versus Tirzepatide
Novo Nordisk’s Wegovy has been on a winning streak as of late, with a metabolic dysfunction-associated steatohepatitis approval last month and prime position in the oral obesity race.
September 2, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Novo Nordisk to streamline operations and reinvest for growth
September 10, 2025
·
4 min read
C-suite
Novo Nordisk Names New Leader, Cuts 2025 Sales Guidance By 5%
In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its semaglutide franchise in the U.S.—and named current international operations head Maziar Mike Doustdar as its new president and CEO.
July 29, 2025
·
2 min read
·
Heather McKenzie
Weight loss
Novo Nordisk’s Termination of Hims & Hers Deal Reignites Compounding Row
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the “litigation risk is back on the table” now that the Danish pharma has stepped away.
July 9, 2025
·
4 min read
·
Nick Paul Taylor
MASH
Novo Wins MASH Approval for Wegovy
The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according to analysts at BMO Capital Markets.
August 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being
September 16, 2025
·
6 min read
Tariffs
Novo Opposes Pharma Tariffs, Urges Crackdown on Illicit Chinese Semaglutide
In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, constitutes a national security threat to the U.S.
May 29, 2025
·
2 min read
·
Tristan Manalac
1 of 58,577
Next
